Please use this identifier to cite or link to this item:
Title: Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Author: Rodriguez, Celestino
Garcia, Trinidad
Areces, Débora
Fernandez, Estrella
Garcia-Noriega, Marcelino
Domingo i Pedrol, Joan Carles
Keywords: Trastorns per dèficit d'atenció amb hiperactivitat en els adults
Suplements nutritius
Attention deficit disorder with hyperactivity in adults
Dietary supplements
Issue Date: 14-Apr-2019
Publisher: Dove Medical Press
Abstract: Background: Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in terms of etiology, clinical presentation, and treatment outcome. Pharmacological and psychological interventions are recommended as primary treatments in ADHD; however, other nonpharmacological intervention such as a dietary supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) has emerged as an attractive option. Purpose: The objective of the present study was to assess whether dietary supplementation with highly concentrated ω-3 docosahexaenoic acid (DHA) triglyceride may improve symptoms in ADHD. Method: A 6-month prospective double-blind placebo-controlled randomized clinical trial was designed in 66 patients with ADHD, aged between 6 and 18 years. Participants in the experimental group received a combination of ω-3 fatty acids (DHA 1,000 mg, eicosapentaenoic acid 90 mg, and docosapentaenoic acid 150 mg). Instruments included d2-test, AULA Nesplora, EDAH scales, and abbreviated Conner's Rating Scale. Results: In the cognitive test, between-group differences were not found, but within-group differences were of a greater magnitude in the DHA group. Between-group differences in favor of the DHA arm were observed in behavioral measures, which were already detected after 3 months of treatment. Results were not changed when adjusted by ADHD medication. Conclusions: This study provides further evidence of the beneficial effect of supplementation with ω-3 DHA in the management of ADHD.
Note: Reproducció del document publicat a:
It is part of: Neuropsychiatric Disease and Treatment, 2019, vol. 15, p. 1193-1209
Related resource:
ISSN: 1176-6328
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
698484.pdf350.96 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons